VRTX
Vertex Pharmaceuticals Incorporated · Healthcare · Biotechnology
Momentum-inputs (vergelijkbare managers):
breedte van houders -9.5% ·
aandelenstroom +0.6% ·
netto nieuwe posities -10.5%
· formule
Geconcentreerde accumulatie: stijgende aandelen bij minder houders
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q1 2025
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 1.30M | $664.72M | n/a | n/a |
| Q2 2026 | 173 | -1 | 210.42M | $104.38B | +5 | −7 |
| Q1 2026 | 178 | 0 | 208.95M | $93.29B | +5 | −6 |
| Q4 2025 | 177 | -1 | 219.78M | $99.62B | +2 | −2 |
| Q3 2025 | 26 | +1 | 120.93M | $47.35B | +1 | −1 |
| Q2 2025 | 23 | +1 | 112.15M | $49.92B | +3 | −2 |
| Q1 2025 | 19 | -2 | 60.41M | $29.28B | n/a | −2 |
| Q4 2024 | 21 | +1 | 60.08M | $24.19B | +1 | n/a |
| Q3 2024 | 19 | 0 | 46.24M | $21.49B | n/a | n/a |
| Q2 2024 | 19 | n/a | 46.47M | $21.77B | n/a | n/a |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Capital World Investors ✦ | 28.53M | +0.7% | $13.83B | 2.2% | ▲ Add | 4 | SEC ↗ |
| 2 | State Street Global Advisors ✦ (passief) | 11.79M | -1.6% | $5.72B | 0.2% | ▼ Trim | 2 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passief) | 5.76M | +2.0% | $2.78B | 0.2% | ▲ Add | 4 | SEC ↗ ×2 |
| 4 | Wellington Management ✦ | 5.45M | -7.8% | $2.64B | 0.5% | ▼ Trim | 4 | SEC ↗ ×8 |
| 5 | Norges Bank ✦ (passief) | 3.36M | -1.5% | $1.63B | 0.2% | ▼ Trim | 4 | SEC ↗ |
| 6 | T. Rowe Price ✦ | 2.92M | +72.5% | $1.41B | 0.2% | ▲ Add | 4 | SEC ↗ ×2 |
| 7 | Renaissance Technologies ✦ | 1.17M | -16.1% | $568.00M | 0.9% | ▼ Trim | 4 | SEC ↗ |
| 8 | Adage Capital Partners ✦ | 489.67K | +134.0% | $237.40M | 0.4% | ▲ Add | 4 | SEC ↗ |
| 9 | Millennium Management ✦ | 309.94K | -0.2% | $150.26M | 0.2% | ▼ Trim | 4 | SEC ↗ |
| 10 | AQR Capital Management ✦ | 145.87K | -40.6% | $69.63M | 0.1% | ▼ Trim | 4 | SEC ↗ ×5 |
| 11 | Marshall Wace ✦ | 138.00K | -28.9% | $66.91M | 0.1% | ▼ Trim | 4 | SEC ↗ ×2 |
| 12 | Baillie Gifford ✦ | 134.47K | -10.3% | $65.19M | 0.1% | ▼ Trim | 4 | SEC ↗ ×4 |
| 13 | D. E. Shaw & Co. ✦ | 71.93K | -72.9% | $34.87M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 14 | Tweedy, Browne ✦ | 38.32K | -5.7% | $18.58M | 1.6% | ▼ Trim | 4 | SEC ↗ |
| 15 | Fisher Asset Management ✦ | 30.67K | +2.5% | $14.87M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 16 | Gotham Asset Management ✦ | 27.78K | -7.8% | $13.47M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 17 | ARK Investment Management ✦ | 26.34K | +3.9% | $12.77M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 18 | Citadel Advisors ✦ | 5.02K | -96.9% | $2.43M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 19 | Two Sigma Investments ✦ | 4.12K | -87.6% | $2.00M | 0.0% | ▼ Trim | 4 | SEC ↗ |
"Hun weging" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die manager: de overtuigingsmaatstaf. ✦ = gecureerde manager.
Nieuwe kopers
| Geen nieuwe bijgehouden kopers dit kwartaal. |
Verlaten
| Arrowstreet Capital | $3.73M | was 0.0% |
| Bridgewater Associates | $285,917 | was 0.0% |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 1,678 houders, 225.07M aandelen, $98.10B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect het vaakst nog meer bezitten: aantallen gedeeld eigendom, geen fundamentele relaties.